Advertisement.
Advertisement.
Advertisement
Advertisement.
TCON TRACON Pharmaceuticals Inc
9,326
| Market Cap | $1.75M |
| Volume | 1,578.00 |
| 52-Wk High | $14.75 |
| 52-Wk Low | $0.60 |
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
Globe Newswire•4 months ago
ENVASARC Trial is Fully Enrolled and Final Data are Expected in Third Quarter 2024 SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage...
Share to Feed
Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON Research Report) yesterday and set a price target of...
TipRanks Financial Blog•5 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly•5 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly•5 months ago
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
Globe Newswire•5 months ago
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
Globe Newswire•5 months ago